Carna Biosciences (TSE:4572) Cyclically Adjusted Revenue per Share: 円0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
43 GF Score
Price 円302.00
GF Value 円186.53
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Carna Biosciences Cyclically Adjusted Revenue per Share?

Carna Biosciences TSE:4572 -1.31% 43 Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 43/100 and a GF Value™ of 円186.53 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Carna Biosciences's adjusted revenue per share for the three months ended in Dec. 2025 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Carna Biosciences was 6.20% per year. The lowest was 2.50% per year. And the median was 3.80% per year.

As of today (2026-07-25), Carna Biosciences's current stock price is 円302.00. Carna Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was 円0.00. Carna Biosciences's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carna Biosciences was 24.41. The lowest was 1.69. And the median was 8.21.


Carna Biosciences  (TSE:4572) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carna Biosciences was 24.41. The lowest was 1.69. And the median was 8.21.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Carna Biosciences Cyclically Adjusted Revenue per Share Related Terms


Carna Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Cyclically Adjusted Revenue per Share Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.60 128.75 130.58 0.00 0.00

Carna Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.37 129.97 0.00 0.00 0.00

TSE:4572 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Carna Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Cyclically Adjusted PS Ratio falls into.


TSE:4572
43GF Score
Carna Biosciences Inc TSE:4572
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Carna Biosciences's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Carna Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 30.691 98.100 35.353
201603 25.086 97.900 28.955
201606 23.545 98.100 27.121
201609 14.995 98.000 17.290
201612 24.936 98.400 28.636
201703 21.148 98.100 24.360
201706 14.037 98.500 16.103
201709 16.400 98.800 18.757
201712 18.240 99.400 20.736
201803 22.106 99.200 25.181
201806 19.535 99.200 22.253
201809 19.442 99.900 21.991
201812 16.554 99.700 18.762
201903 16.622 99.700 18.839
201906 211.390 99.800 239.349
201909 35.023 100.100 39.536
201912 29.371 100.500 33.024
202003 27.717 100.300 31.227
202006 19.727 99.900 22.314
202009 21.603 99.900 24.436
202012 23.035 99.300 26.213
202103 18.648 99.900 21.093
202106 15.986 99.500 18.155
202109 15.741 100.100 17.770
202112 103.773 100.100 117.146
202203 41.235 101.100 46.089
202206 20.851 101.800 23.145
202209 18.740 103.100 20.539
202212 20.487 104.100 22.239
202303 14.329 104.400 15.509
202306 16.005 105.200 17.192
202309 12.291 106.200 13.078
202312 53.332 106.800 56.428
202403 10.549 107.200 11.120
202406 7.467 108.200 7.798
202412 0.000 110.700 0.000
202503 7.505 111.100 7.633
202506 5.642 111.700 5.708
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
Carna Biosciences (TSE:4572) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Cyclically Adjusted Revenue per Share too high?
Carna Biosciences' current Cyclically Adjusted Revenue per Share is 円0.00. Overall, Carna Biosciences has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Carna Biosciences' Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円186.53, compared to a current price of 円302.00 — trading 61.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. Carna Biosciences' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円302.00 is trading 61.9% above its estimated GF Value™ of 円186.53. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円186.53 vs. price of 円302.00 (61.9% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
43GF Score

Get the complete analysis for TSE:4572

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円302.00
Price
円186.53
GF Value